Cas no 118409-57-7 (Tyrphostin 23)

Tyrphostin 23 is a selective inhibitor of protein tyrosine kinases, particularly effective in targeting epidermal growth factor receptor (EGFR) tyrosine kinase activity. This compound is widely utilized in biochemical and pharmacological research to study signal transduction pathways involving tyrosine phosphorylation. Tyrphostin 23 exhibits competitive inhibition by binding to the ATP site of EGFR, making it a valuable tool for investigating cellular proliferation, differentiation, and oncogenic processes. Its high specificity and well-characterized mechanism of action contribute to its reliability in experimental applications. Researchers favor Tyrphostin 23 for its ability to dissect kinase-dependent pathways with precision, aiding in the study of cancer and other tyrosine kinase-related disorders.

Tyrphostin 23 structure

Product Name:Tyrphostin 23

CAS No:118409-57-7

MF:C₁₀H₆N₂O₂

MW:186.166841983795

MDL:MFCD00133899

CID:165430

PubChem ID:24278041

Update Time:2025-06-29

Tyrphostin 23 Chemical and Physical Properties

Names and Identifiers

- Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-
- Tyrphostin 23
- Tyrphostin A23
- AG-18
- AG-18 (AG18, Tyrphostin A23, RG-50810)
- (3,4-Dihydroxybenzylidene)malononitrile RG-50810
- 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile
- RG 50810
- RG-50810
- AG18
- (3,4-Dihydroxybenzylidene)malononitrile
- 2-(3,4-Dihydroxybenzylidene)malononitrile
- AG 18 (pharmaceutical)
- RG 50858
- TX 825
- Tyrphostin AG 18
- Tyrphostin AG 1
- AG-18(RG-50810)
- Tyrphostin A 23
- AG18, >=98%
- AG 18
- Tyrphostin AG18
- Tyrphostin RG50810
- alpha-Cyano-(3,4-dihydroxy)cinnamonitrile
- (3,4-Dihydroxyphenyl)methylene propanedinitrile
- RV0GCD31OJ
- C10H6N2O2
- (3,4-dihydroxybenzylidene)propanedinitrile
- DS
- AS-69033
- BRD-K49657628-001-03-1
- tyrphostin-23
- HMS3369M02
- T3503
- CHEBI:92862
- NCGC00016043-04
- FT-0675716
- BiomolKI_000011
- ((3,4-Dihydroxyphenyl)methylene)-Propanedinitrile
- AG 18 (Tyrphostin 23)
- NCGC00016043-01
- Tox21_110287_1
- BRD-K49657628-001-05-6
- DTXSID9045215
- NCGC00016043-03
- DTXCID7025215
- SR-01000075506-3
- SCHEMBL241922
- CAS-118409-57-7
- NCGC00024615-02
- tyrphostin-AG-18
- LP01160
- HSCI1_000108
- Tocris-0493
- 3,4-(Dihydroxybenzylidene)malononitrile
- s8009
- NCGC00016043-07
- NCGC00024615-04
- HMS3263H21
- Lopac-T-7165
- T 7165
- EX-A901
- F6782-3631
- 118409-57-7
- SR-01000075506
- MFCD00133899
- NCGC00016043-17
- UNII-RV0GCD31OJ
- EU-0101160
- HMS2233I22
- BCP06838
- NCGC00016043-08
- AKOS005715658
- ((3,4-DIHYDROXYPHENYL)METHYLENE)-PROPENEDINITRILE
- Lopac0_001160
- NCGC00024615-01
- BMK1-B11
- SW219523-1
- SDCCGSBI-0051127.P002
- CCG-100615
- AG-18 (Tyrphostin 23)
- [(3,4-Dihydroxyphenyl)methylene]-propenedinitrile
- NCGC00016043-02
- AG18;Tyrphostin 23; RG-50810
- Tox21_501160
- cid_2052
- SMR001230729
- Oprea1_072726
- HMS3266E18
- NCGC00016043-05
- Tyrphostin 23;Tyrphostin A23; RG-50810; AG 18
- HY-15644
- HMS3678G15
- SR-01000075506-1
- SR-01000075506-6
- BDBM4339
- Q27164614
- J-003744
- 2-[(3,4-dihydroxyphenyl)methylene]-propanedinitrile
- 2-(3,4-Dihydroxy-benzylidene)-malononitrile
- AG 18 - CAS 118409-57-7
- NCGC00024615-03
- HMS3653D19
- benzylidenemalononitrile (BMN) deriv. 23
- BiomolKI2_000021
- BRD-K49657628-001-02-3
- AC-30286
- MLS002153315
- NCGC00261845-01
- NCGC00016043-06
- Tyrphostin 23, >=98%
- Propanedinitrile, ((3,4-dihydroxyphenyl)methylene)-
- HMS3414G15
- 3,4-Dihydroxybenzylidene malononitrile
- Tox21_110287
- VTJXFTPMFYAJJU-UHFFFAOYSA-N
- CHEMBL76904
- CS-1387
- AG18，RG-50810， Tyrphostin A23
- STL139213
- BRD-K49657628-001-15-5
- SDCCGSBI-0051127.P005
- BRD-K49657628-001-13-0
- DB-093180
- BRD-K49657628-001-14-8
- AG-18?
- MDL： MFCD00133899
- Inchi： 1S/C10H6N2O2/c11-5-8(6-12)3-7-1-2-9(13)10(14)4-7/h1-4,13-14H
- InChI Key： VTJXFTPMFYAJJU-UHFFFAOYSA-N
- SMILES： OC1=C(C=CC(/C=C(\C#N)/C#N)=C1)O

Computed Properties

Exact Mass: 186.04300
Monoisotopic Mass: 186.042927
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 4
Heavy Atom Count: 14
Rotatable Bond Count: 1
Complexity: 313
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
XLogP3: 1.3
Topological Polar Surface Area: 88
Surface Charge: 0
Tautomer Count: 13

Experimental Properties

Color/Form: solid
Density: 1.428±0.06 g/cm3 (20 oC 760 Torr),
Melting Point: 225 oC
Boiling Point: 421.1°C at 760 mmHg
Flash Point: 208.5±28.7 °C
Refractive Index: 1.70
Solubility: Slightly soluble (3.9 g/l) (25 o C),
Stability/Shelf Life: Store in refrigerator
PSA: 88.04000
LogP: 1.52836
λmax: 464(DMSO)(lit.)
Solubility: Not determined

Tyrphostin 23 Security Information

Symbol:
Prompt：warning
Signal Word：Warning
Hazard Statement： H371-H373
Warning Statement： P260-P264-P270-P308+P311-P405-P501
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：3
Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Tyrphostin 23 Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
MedChemExpress	HY-15644-10mM*1mLinDMSO	Tyrphostin 23	118409-57-7	98.80%	10mM*1mLinDMSO	￥614	2022-05-18
MedChemExpress	HY-15644-10mg	Tyrphostin 23	118409-57-7	99.43%	10mg	￥558	2024-04-20
MedChemExpress	HY-15644-50mg	Tyrphostin 23	118409-57-7	99.43%	50mg	￥1989	2024-04-20
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.	T3503-100MG	Tyrphostin A23	118409-57-7	>98.0%(GC)	100mg	￥700.00	2024-04-18
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	T129445-250mg	Tyrphostin 23	118409-57-7	≥98%	250mg	￥3800.90	2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	T129445-10mg	Tyrphostin 23	118409-57-7	≥98%	10mg	￥392.90	2023-08-31
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	T129445-50mg	Tyrphostin 23	118409-57-7	≥98%	50mg	￥1317.90	2023-08-31
DC Chemicals	DC7051-100 mg	AG-18	118409-57-7	>98%	100mg	$250.0	2022-03-01
DC Chemicals	DC7051-250 mg	AG-18	118409-57-7	>98%	250mg	$500.0	2022-03-01
DC Chemicals	DC7051-1 g	AG-18	118409-57-7	>98%	1g	$1100.0	2022-03-01

Tyrphostin 23 Production Method

Tyrphostin 23 Suppliers

Amadis Chemical Company Limited

Gold Member

Audited Supplier

(CAS:118409-57-7)Tyrphostin 23

Order Number:A854355

Stock Status:in Stock

Quantity:250mg

Purity:99%

Pricing Information Last Updated:Friday, 30 August 2024 07:50

Price ($):462.0

Email:[email protected]

Product Official Link

Tyrphostin 23 Related Literature

1. Ultralow thermal conductivity of Tl4Ag18Te11

Yixuan Shi,Nour Mashmoushi,Wojciech Wegner,Parisa Jafarzadeh,Zahra Sepahi,Abdeljalil Assoud,Holger Kleinke J. Mater. Chem. C 2019 7 8029
2. Preparation of gas phase naked silver cluster cations outside a mass spectrometer from ligand protected clusters in solution

Madhuri Jash,Arthur C. Reber,Atanu Ghosh,Depanjan Sarkar,Mohammad Bodiuzzaman,Pallab Basuri,Ananya Baksi,Shiv N. Khanna,Thalappil Pradeep Nanoscale 2018 10 15714
3. Electronic structure of the mononuclear Ag(ii) complex [Ag([18]aneS4O2)]2+ ([18]aneS4O2 = 1,10-dioxa-4,7,13,16-tetrathiacyclooctadecane)

Deguang Huang,Alexander J. Blake,Eric J. L. McInnes,Jonathan McMaster,E. Stephen Davies,Claire Wilson,Joanna Wolowska,Martin Schr?der Chem. Commun. 2008 1305
4. Electronic structure of the mononuclear Ag(ii) complex [Ag([18]aneS4O2)]2+ ([18]aneS4O2 = 1,10-dioxa-4,7,13,16-tetrathiacyclooctadecane)

Deguang Huang,Alexander J. Blake,Eric J. L. McInnes,Jonathan McMaster,E. Stephen Davies,Claire Wilson,Joanna Wolowska,Martin Schr?der Chem. Commun. 2008 1305
5. Ag18(μ8-S)(p-TBBT)16(PPh3)8: symmetry breaking induced by the core to generate chirality

Fan Tian,Rong Chen Chem. Commun. 2020 56 2719

Related Categories

Additional information on Tyrphostin 23

Tyrphostin 23 (CAS No: 118409-57-7) – A Comprehensive Overview in Modern Chemical Biology

Tyrphostin 23, identified by its Chemical Abstracts Service (CAS) number 118409-57-7, represents a significant compound in the realm of chemical biology. This molecule has garnered considerable attention due to its unique pharmacological properties and its potential applications in modulating key signaling pathways. As research in drug discovery and molecular therapy advances, Tyrphostin 23 has emerged as a compound of interest, particularly in the context of its role in cellular communication and disease intervention.

The molecular structure of Tyrphostin 23 is meticulously designed to interact with specific targets within cellular pathways. Its chemical composition, characterized by a complex arrangement of functional groups, allows it to exhibit potent effects on protein tyrosine kinases (PTKs). These kinases are pivotal enzymes involved in numerous physiological processes, including cell growth, differentiation, and survival. By inhibiting the activity of PTKs, Tyrphostin 23 can modulate these processes, making it a valuable tool in both research and therapeutic contexts.

In recent years, the study of Tyrphostin 23 has been extensively explored in relation to its potential applications in cancer research. Cancer is fundamentally a disease of uncontrolled cell proliferation and division, often driven by aberrant signaling through PTKs. Preclinical studies have demonstrated that Tyrphostin 23 can effectively inhibit the activity of certain PTKs associated with cancer progression. This inhibition leads to reduced tumor growth and metastasis, offering a promising avenue for developing novel anticancer therapies.

The mechanism of action of Tyrphostin 23 involves its binding to the active site of PTKs, thereby preventing the phosphorylation of downstream signaling molecules. This disruption in signaling cascades can lead to apoptosis (programmed cell death) or senescence (cellular aging) in cancer cells. Furthermore, research indicates that Tyrphostin 23 may also have applications in treating other diseases characterized by dysregulated PTK activity, such as inflammatory disorders and autoimmune conditions.

Advances in synthetic chemistry have enabled the development of more potent and selective derivatives of Tyrphostin 23. These derivatives maintain the core pharmacophore responsible for PTK inhibition while incorporating modifications that enhance their pharmacokinetic properties. Such improvements are crucial for translating preclinical findings into effective clinical treatments. The synthesis and characterization of these derivatives continue to be an active area of research, with scientists striving to optimize both efficacy and safety profiles.

The impact of Tyrphostin 23 extends beyond academic research. Its potential as a lead compound for drug development has attracted significant interest from pharmaceutical companies. Several clinical trials are underway to evaluate the safety and efficacy of derivatives based on the Tyrphostin 23 scaffold. These trials aim to provide insights into how such compounds can be integrated into broader therapeutic strategies for various diseases.

In conclusion, Tyrphostin 23 (CAS No: 118409-57-7) stands as a testament to the power of chemical biology in uncovering novel therapeutic agents. Its ability to modulate key cellular pathways makes it a versatile tool for both research and clinical applications. As our understanding of disease mechanisms continues to evolve, compounds like Tyrphostin 23 will play an increasingly important role in shaping the future of medicine.

118409-57-7 (Tyrphostin 23) Related Products

Recommended suppliers